

an independent audit in accordance with OMB Circular A-133.

## VII. Agency Contacts

### *Administrative and Budgetary Requirements*

For information related to administrative and budgetary requirements, contact Karen Campbell in the OPHS Office of Grants Management, 1101 Wootton Parkway, Suite 550, Rockville, MD 20852; by phone at 240-453-8822, or by email at [kcampbell@osophs.dhhs.gov](mailto:kcampbell@osophs.dhhs.gov).

### *Program Requirements*

For information related to family planning program requirements, contact the Regional Program Consultant for Family Planning in PHS Region VI (Arkansas, Louisiana, New Mexico, Oklahoma, Texas)—Evelyn Glass, by phone at 214-767-3088, or by email at [eglass@osophs.dhhs.gov](mailto:eglass@osophs.dhhs.gov).

## VIII. Other Information

There will be an opportunity for a technical assistance conference call to be held within one month after publication of this Notice in the **Federal Register**. For more information regarding this opportunity, including date, registration information, and how to join the call, please consult the OPA Web site at <http://opa.osophs.dhhs.gov>.

Dated: March 29, 2006.

**Alma L. Golden,**

*Deputy Assistant Secretary for Population Affairs.*

[FR Doc. E6-5262 Filed 4-10-06; 8:45 am]

**BILLING CODE 4150-34-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### **Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): Research Center and Occupational Safety and Health Training Projects Grants, PAR-05-126**

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

*Name:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Research Center and Occupational Safety and Health Training Projects Grants, PAR-05-126.

*Time And Date:* 10 a.m.–12 p.m., April 25, 2006 (Closed).

*Place:* Teleconference.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

*Matters To Be Discussed:* The meeting will include the review, discussion, and evaluation of applications received in response to: Research Center and Occupational Safety and Health Training Projects Grants, PAR-05-126.

#### **FOR FURTHER INFORMATION CONTACT:**

Charles N. Rafferty, Ph.D., Designated Federal Official, National Institute for Occupational Safety and Health, CDC, 1600 Clifton Road, NE, Mailstop E-74, Atlanta, GA 30333, Telephone Number 404-498-2582.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 5, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6-5241 Filed 4-10-06; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2006N-0130]

#### **Agency Information Collection Activities; Proposed Collection; Comment Request; Food Labeling; Trans Fatty Acids in Nutrition Labeling**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection requirements of FDA's regulations requiring that trans fatty acids be declared in the Nutrition Facts panel of conventional foods and

dietary supplements on a separate line without a percent Daily Value (%DV).

**DATES:** Submit written or electronic comments on the collection of information by June 12, 2006.

**ADDRESSES:** Submit electronic comments on the collection of information to: <http://www.fda.gov/dockets/ecomments>. Submit written comments on the collection of information to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

#### **FOR FURTHER INFORMATION CONTACT:**

Jonna Capezuto, Office of Management Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4659.

**SUPPLEMENTARY INFORMATION:** Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.